CYCC Announces at-the-market $7 Million Strategic Investment
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures
Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor.
- Strategic investment from single biotech-focused institutional investor -
- Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors -
Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock (convertible into shares of common stock at a ratio of 1:5), and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7 million.
The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share.
finance.yahoo.com/ne...ket-7-130000954.html
Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor.
- Strategic investment from single biotech-focused institutional investor -
- Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors -
Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock (convertible into shares of common stock at a ratio of 1:5), and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7 million.
The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share.
finance.yahoo.com/ne...ket-7-130000954.html